Adam T Hagymasi
Overview
Explore the profile of Adam T Hagymasi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singhaviranon S, Dempsey J, Hagymasi A, Mandoiu I, Srivastava P
Nat Immunol
. 2025 Jan;
26(2):240-251.
PMID: 39789375
T cells recognize neoepitope peptide-major histocompatibility complex class I on cancer cells. The strength (or avidity) of the T cell receptor-peptide-major histocompatibility complex class I interaction is a critical variable...
2.
Al Seesi S, Al-Okaily A, Shcheglova T, Sherafat E, Alqahtani F, Hagymasi A, et al.
J Comput Biol
. 2023 Mar;
30(4):538-551.
PMID: 36999902
High-throughput DNA and RNA sequencing are revolutionizing precision oncology, enabling personalized therapies such as cancer vaccines designed to target tumor-specific neoepitopes generated by somatic mutations expressed in cancer cells. Identification...
3.
Hagymasi A, Dempsey J, Srivastava P
Curr Protoc
. 2022 Nov;
2(11):e592.
PMID: 36367390
Heat-shock proteins (HSPs), or stress proteins, are abundant and highly conserved, present in all organisms and in all cells. Selected HSPs, also known as chaperones, play crucial roles in folding...
4.
Ebrahimi-Nik H, Moussa M, Englander R, Singhaviranon S, Michaux J, Pak H, et al.
Nat Commun
. 2021 Nov;
12(1):6423.
PMID: 34741035
High-affinity MHC I-peptide interactions are considered essential for immunogenicity. However, some neo-epitopes with low affinity for MHC I have been reported to elicit CD8 T cell dependent tumor rejection in...
5.
Brennick C, George M, Moussa M, Hagymasi A, Al Seesi S, Shcheglova T, et al.
J Clin Invest
. 2020 Dec;
131(3).
PMID: 33320837
Identification of neoepitopes that are effective in cancer therapy is a major challenge in creating cancer vaccines. Here, using an entirely unbiased approach, we queried all possible neoepitopes in a...
6.
Adler A, Mittal P, Hagymasi A, Menoret A, Shen C, Agliano F, et al.
Oncogene
. 2020 Jan;
39(11):2424-2436.
PMID: 31959897
Metastatic tumors that have become resistant to androgen deprivation therapy represent the major challenge in treating prostate cancer. Although these recurrent tumors typically remain dependent on the androgen receptor (AR),...
7.
Mittal P, Abblett R, Ryan J, Hagymasi A, Agyekum-Yamoah A, Svedova J, et al.
J Immunol
. 2018 Jan;
200(4):1513-1526.
PMID: 29305435
Agonists to the TNF/TNFR costimulatory receptors CD134 (OX40) and CD137 (4-1BB) elicit antitumor immunity. Dual costimulation with anti-CD134 plus anti-CD137 is particularly potent because it programs cytotoxic potential in CD8...
8.
Acharya N, Penukonda S, Shcheglova T, Hagymasi A, Basu S, Srivastava P
Proc Natl Acad Sci U S A
. 2017 Apr;
114(19):5005-5010.
PMID: 28439004
Endogenous cannabinoids (endocannabinoids) are small molecules biosynthesized from membrane glycerophospholipid. Anandamide (AEA) is an endogenous intestinal cannabinoid that controls appetite and energy balance by engagement of the enteric nervous system...
9.
St Rose M, Taylor R, Bandyopadhyay S, Qui H, Hagymasi A, Vella A, et al.
Immunol Cell Biol
. 2013 Jan;
91(2):173-83.
PMID: 23295363
T-cell tolerance to tumor antigens represents a major hurdle in generating tumor immunity. Combined administration of agonistic monoclonal antibodies (mAbs) to the costimulatory receptors CD134 plus CD137 can program T-cells...
10.
Qui H, Hagymasi A, Bandyopadhyay S, St Rose M, Ramanarasimhaiah R, Menoret A, et al.
J Immunol
. 2011 Sep;
187(7):3555-64.
PMID: 21880986
Cytotoxic CD4 Th1 cells are emerging as a therapeutically useful T cell lineage that can effectively target tumors, but until now the pathways that govern their differentiation have been poorly...